TherapeuticsMD, Inc. (TXMD) Stock Competitors & Peer Comparison
See (TXMD) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXMD | $2.04 | -3.77% | 23.6M | 204.00 | $0.01 | N/A |
| TAK | $15.18 | -0.07% | 48B | 39.95 | $0.38 | +4.08% |
| HLN | $8.70 | -1.58% | 38.7B | 17.41 | $0.50 | +2.22% |
| TEVA | $32.58 | -5.95% | 38.5B | 24.69 | $1.34 | N/A |
| VTRS | $15.69 | -0.76% | 18.3B | -52.30 | -$0.30 | +3.05% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.57 | -0.42% | 11.8B | -47.31 | -$0.50 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RGC | $23.15 | -4.22% | 11.4B | -2315.00 | -$0.01 | N/A |
| RDY | $12.96 | -2.26% | 10.8B | 24.58 | $0.53 | +0.70% |
Stock Comparison
TXMD vs TAK Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TAK has a market cap of 48B. Regarding current trading prices, TXMD is priced at $2.04, while TAK trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TAK's P/E ratio is 39.95. In terms of profitability, TXMD's ROE is +0.01%, compared to TAK's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TAK's competition here
TXMD vs HLN Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, HLN has a market cap of 38.7B. Regarding current trading prices, TXMD is priced at $2.04, while HLN trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas HLN's P/E ratio is 17.41. In terms of profitability, TXMD's ROE is +0.01%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TXMD is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check HLN's competition here
TXMD vs TEVA Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TEVA has a market cap of 38.5B. Regarding current trading prices, TXMD is priced at $2.04, while TEVA trades at $32.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TEVA's P/E ratio is 24.69. In terms of profitability, TXMD's ROE is +0.01%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, TXMD is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TEVA's competition here
TXMD vs VTRS Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, VTRS has a market cap of 18.3B. Regarding current trading prices, TXMD is priced at $2.04, while VTRS trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas VTRS's P/E ratio is -52.30. In terms of profitability, TXMD's ROE is +0.01%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, TXMD is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check VTRS's competition here
TXMD vs ITCI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TXMD is priced at $2.04, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TXMD's ROE is +0.01%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ITCI's competition here
TXMD vs ELAN Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, TXMD is priced at $2.04, while ELAN trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ELAN's P/E ratio is -47.31. In terms of profitability, TXMD's ROE is +0.01%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, TXMD is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ELAN's competition here
TXMD vs CTLT Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TXMD is priced at $2.04, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TXMD's ROE is +0.01%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TXMD is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CTLT's competition here
TXMD vs RGC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, RGC has a market cap of 11.4B. Regarding current trading prices, TXMD is priced at $2.04, while RGC trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas RGC's P/E ratio is -2315.00. In terms of profitability, TXMD's ROE is +0.01%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TXMD is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check RGC's competition here
TXMD vs RDY Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, RDY has a market cap of 10.8B. Regarding current trading prices, TXMD is priced at $2.04, while RDY trades at $12.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas RDY's P/E ratio is 24.58. In terms of profitability, TXMD's ROE is +0.01%, compared to RDY's ROE of +0.12%. Regarding short-term risk, TXMD is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check RDY's competition here
TXMD vs LNTH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, LNTH has a market cap of 6.3B. Regarding current trading prices, TXMD is priced at $2.04, while LNTH trades at $96.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas LNTH's P/E ratio is 22.98. In terms of profitability, TXMD's ROE is +0.01%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, TXMD is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check LNTH's competition here
TXMD vs INDV Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, TXMD is priced at $2.04, while INDV trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas INDV's P/E ratio is 17.29. In terms of profitability, TXMD's ROE is +0.01%, compared to INDV's ROE of -1.42%. Regarding short-term risk, TXMD is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check INDV's competition here
TXMD vs AMRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AMRX has a market cap of 4B. Regarding current trading prices, TXMD is priced at $2.04, while AMRX trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AMRX's P/E ratio is 34.18. In terms of profitability, TXMD's ROE is +0.01%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, TXMD is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AMRX's competition here
TXMD vs SUPN Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, TXMD is priced at $2.04, while SUPN trades at $43.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SUPN's P/E ratio is -86.41. In terms of profitability, TXMD's ROE is +0.01%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, TXMD is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SUPN's competition here
TXMD vs DCPH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $2.04, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TXMD's ROE is +0.01%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TXMD is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check DCPH's competition here
TXMD vs AVDL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.04, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TXMD's ROE is +0.01%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, TXMD is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AVDL's competition here
TXMD vs HCM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, HCM has a market cap of 2B. Regarding current trading prices, TXMD is priced at $2.04, while HCM trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas HCM's P/E ratio is 4.35. In terms of profitability, TXMD's ROE is +0.01%, compared to HCM's ROE of +0.41%. Regarding short-term risk, TXMD is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check HCM's competition here
TXMD vs EMBCV Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $2.04, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TXMD's ROE is +0.01%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, TXMD is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check EMBCV's competition here
TXMD vs BHC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, BHC has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $2.04, while BHC trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas BHC's P/E ratio is -1.55. In terms of profitability, TXMD's ROE is +0.01%, compared to BHC's ROE of +1.21%. Regarding short-term risk, TXMD is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check BHC's competition here
TXMD vs DVAX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $2.04, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TXMD's ROE is +0.01%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, TXMD is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check DVAX's competition here
TXMD vs ANIP Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TXMD is priced at $2.04, while ANIP trades at $74.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ANIP's P/E ratio is 19.09. In terms of profitability, TXMD's ROE is +0.01%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, TXMD is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ANIP's competition here
TXMD vs TARO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.04, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TARO's P/E ratio is 30.05. In terms of profitability, TXMD's ROE is +0.01%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TARO's competition here
TXMD vs PRGO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, TXMD is priced at $2.04, while PRGO trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PRGO's P/E ratio is -0.81. In terms of profitability, TXMD's ROE is +0.01%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, TXMD is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check PRGO's competition here
TXMD vs HROW Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $2.04, while HROW trades at $32.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas HROW's P/E ratio is -86.47. In terms of profitability, TXMD's ROE is +0.01%, compared to HROW's ROE of -0.34%. Regarding short-term risk, TXMD is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check HROW's competition here
TXMD vs PAHC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $2.04, while PAHC trades at $28.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PAHC's P/E ratio is 12.23. In terms of profitability, TXMD's ROE is +0.01%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TXMD is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check PAHC's competition here
TXMD vs EVO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EVO has a market cap of 1B. Regarding current trading prices, TXMD is priced at $2.04, while EVO trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EVO's P/E ratio is -4.68. In terms of profitability, TXMD's ROE is +0.01%, compared to EVO's ROE of -0.24%. Regarding short-term risk, TXMD is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check EVO's competition here
TXMD vs CRON Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, TXMD is priced at $2.04, while CRON trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CRON's P/E ratio is -136.50. In terms of profitability, TXMD's ROE is +0.01%, compared to CRON's ROE of -0.00%. Regarding short-term risk, TXMD is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CRON's competition here
TXMD vs COLL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, COLL has a market cap of 988.3M. Regarding current trading prices, TXMD is priced at $2.04, while COLL trades at $30.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas COLL's P/E ratio is 14.79. In terms of profitability, TXMD's ROE is +0.01%, compared to COLL's ROE of +0.27%. Regarding short-term risk, TXMD is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check COLL's competition here
TXMD vs ALVO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ALVO has a market cap of 936.1M. Regarding current trading prices, TXMD is priced at $2.04, while ALVO trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ALVO's P/E ratio is 30.00. In terms of profitability, TXMD's ROE is +0.01%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, TXMD is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ALVO's competition here
TXMD vs PETQ Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TXMD is priced at $2.04, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TXMD's ROE is +0.01%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check PETQ's competition here
TXMD vs PCRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PCRX has a market cap of 875.2M. Regarding current trading prices, TXMD is priced at $2.04, while PCRX trades at $22.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PCRX's P/E ratio is 171.15. In terms of profitability, TXMD's ROE is +0.01%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check PCRX's competition here
TXMD vs AMPH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AMPH has a market cap of 813.5M. Regarding current trading prices, TXMD is priced at $2.04, while AMPH trades at $18.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AMPH's P/E ratio is 11.11. In terms of profitability, TXMD's ROE is +0.01%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TXMD is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AMPH's competition here
TXMD vs TLRY Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TLRY has a market cap of 643.5M. Regarding current trading prices, TXMD is priced at $2.04, while TLRY trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TLRY's P/E ratio is -0.37. In terms of profitability, TXMD's ROE is +0.01%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, TXMD is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TLRY's competition here
TXMD vs BDSI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TXMD is priced at $2.04, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TXMD's ROE is +0.01%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TXMD is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check BDSI's competition here
TXMD vs IRWD Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, IRWD has a market cap of 539.9M. Regarding current trading prices, TXMD is priced at $2.04, while IRWD trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas IRWD's P/E ratio is 5.29. In terms of profitability, TXMD's ROE is +0.01%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, TXMD is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check IRWD's competition here
TXMD vs CGC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CGC has a market cap of 451.4M. Regarding current trading prices, TXMD is priced at $2.04, while CGC trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CGC's P/E ratio is -0.79. In terms of profitability, TXMD's ROE is +0.01%, compared to CGC's ROE of -0.51%. Regarding short-term risk, TXMD is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CGC's competition here
TXMD vs KMDA Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, KMDA has a market cap of 433.2M. Regarding current trading prices, TXMD is priced at $2.04, while KMDA trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas KMDA's P/E ratio is 21.46. In terms of profitability, TXMD's ROE is +0.01%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TXMD is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check KMDA's competition here
TXMD vs EOLS Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EOLS has a market cap of 406.3M. Regarding current trading prices, TXMD is priced at $2.04, while EOLS trades at $6.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EOLS's P/E ratio is -9.35. In terms of profitability, TXMD's ROE is +0.01%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, TXMD is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check EOLS's competition here
TXMD vs AQST Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AQST has a market cap of 390.3M. Regarding current trading prices, TXMD is priced at $2.04, while AQST trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AQST's P/E ratio is -6.44. In terms of profitability, TXMD's ROE is +0.01%, compared to AQST's ROE of +1.91%. Regarding short-term risk, TXMD is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AQST's competition here
TXMD vs SNDL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SNDL has a market cap of 373.2M. Regarding current trading prices, TXMD is priced at $2.04, while SNDL trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SNDL's P/E ratio is -48.00. In terms of profitability, TXMD's ROE is +0.01%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, TXMD is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SNDL's competition here
TXMD vs SIGA Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SIGA has a market cap of 309.8M. Regarding current trading prices, TXMD is priced at $2.04, while SIGA trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SIGA's P/E ratio is 15.43. In terms of profitability, TXMD's ROE is +0.01%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, TXMD is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SIGA's competition here
TXMD vs ALIM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TXMD is priced at $2.04, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is +0.01%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TXMD is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ALIM's competition here
TXMD vs ORGO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ORGO has a market cap of 288.2M. Regarding current trading prices, TXMD is priced at $2.04, while ORGO trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ORGO's P/E ratio is -18.67. In terms of profitability, TXMD's ROE is +0.01%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, TXMD is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ORGO's competition here
TXMD vs TKNO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TKNO has a market cap of 277.7M. Regarding current trading prices, TXMD is priced at $2.04, while TKNO trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TKNO's P/E ratio is -16.71. In terms of profitability, TXMD's ROE is +0.01%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, TXMD is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TKNO's competition here
TXMD vs LNDC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TXMD is priced at $2.04, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TXMD's ROE is +0.01%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, TXMD is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check LNDC's competition here
TXMD vs TYHT Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TXMD is priced at $2.04, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TXMD's ROE is +0.01%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, TXMD is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TYHT's competition here
TXMD vs EMBC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EMBC has a market cap of 207.1M. Regarding current trading prices, TXMD is priced at $2.04, while EMBC trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EMBC's P/E ratio is 1.85. In terms of profitability, TXMD's ROE is +0.01%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, TXMD is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check EMBC's competition here
TXMD vs LFCR Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, LFCR has a market cap of 204.4M. Regarding current trading prices, TXMD is priced at $2.04, while LFCR trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas LFCR's P/E ratio is -4.29. In terms of profitability, TXMD's ROE is +0.01%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, TXMD is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check LFCR's competition here
TXMD vs ACB Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ACB has a market cap of 199M. Regarding current trading prices, TXMD is priced at $2.04, while ACB trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ACB's P/E ratio is -3.25. In terms of profitability, TXMD's ROE is +0.01%, compared to ACB's ROE of -0.08%. Regarding short-term risk, TXMD is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ACB's competition here
TXMD vs REPH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TXMD is priced at $2.04, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas REPH's P/E ratio is -8.04. In terms of profitability, TXMD's ROE is +0.01%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check REPH's competition here
TXMD vs DERM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, DERM has a market cap of 165.7M. Regarding current trading prices, TXMD is priced at $2.04, while DERM trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas DERM's P/E ratio is -16.27. In terms of profitability, TXMD's ROE is +0.01%, compared to DERM's ROE of -0.36%. Regarding short-term risk, TXMD is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check DERM's competition here
TXMD vs THTX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TXMD is priced at $2.04, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas THTX's P/E ratio is -17.84. In terms of profitability, TXMD's ROE is +0.01%, compared to THTX's ROE of +0.47%. Regarding short-term risk, TXMD is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check THTX's competition here
TXMD vs OGI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, OGI has a market cap of 153.4M. Regarding current trading prices, TXMD is priced at $2.04, while OGI trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas OGI's P/E ratio is -7.27. In terms of profitability, TXMD's ROE is +0.01%, compared to OGI's ROE of -0.07%. Regarding short-term risk, TXMD is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check OGI's competition here
TXMD vs ASRT Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ASRT has a market cap of 151.5M. Regarding current trading prices, TXMD is priced at $2.04, while ASRT trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ASRT's P/E ratio is -4.23. In terms of profitability, TXMD's ROE is +0.01%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TXMD is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ASRT's competition here
TXMD vs CRDL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CRDL has a market cap of 128.7M. Regarding current trading prices, TXMD is priced at $2.04, while CRDL trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CRDL's P/E ratio is -4.11. In terms of profitability, TXMD's ROE is +0.01%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, TXMD is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CRDL's competition here
TXMD vs SCTL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TXMD is priced at $2.04, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TXMD's ROE is +0.01%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SCTL's competition here
TXMD vs PROC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TXMD is priced at $2.04, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PROC's P/E ratio is 1.53. In terms of profitability, TXMD's ROE is +0.01%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check PROC's competition here
TXMD vs OPTN Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TXMD is priced at $2.04, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TXMD's ROE is +0.01%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, TXMD is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check OPTN's competition here
TXMD vs ZOM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TXMD is priced at $2.04, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TXMD's ROE is +0.01%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, TXMD is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ZOM's competition here
TXMD vs GRVI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TXMD is priced at $2.04, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TXMD's ROE is +0.01%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TXMD is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check GRVI's competition here
TXMD vs CPIX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CPIX has a market cap of 86.5M. Regarding current trading prices, TXMD is priced at $2.04, while CPIX trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CPIX's P/E ratio is -11.78. In terms of profitability, TXMD's ROE is +0.01%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, TXMD is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CPIX's competition here
TXMD vs ZYNE Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TXMD is priced at $2.04, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TXMD's ROE is +0.01%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TXMD is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ZYNE's competition here
TXMD vs SSIC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TXMD is priced at $2.04, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TXMD's ROE is +0.01%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TXMD is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SSIC's competition here
TXMD vs BGM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, BGM has a market cap of 65.2M. Regarding current trading prices, TXMD is priced at $2.04, while BGM trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas BGM's P/E ratio is -1.12. In terms of profitability, TXMD's ROE is +0.01%, compared to BGM's ROE of -0.03%. Regarding short-term risk, TXMD is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check BGM's competition here
TXMD vs VLNS Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TXMD is priced at $2.04, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TXMD's ROE is +0.01%, compared to VLNS's ROE of N/A. Regarding short-term risk, TXMD is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check VLNS's competition here
TXMD vs DRRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TXMD is priced at $2.04, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TXMD's ROE is +0.01%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, TXMD is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check DRRX's competition here
TXMD vs INCR Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, INCR has a market cap of 55.8M. Regarding current trading prices, TXMD is priced at $2.04, while INCR trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas INCR's P/E ratio is -4.44. In terms of profitability, TXMD's ROE is +0.01%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check INCR's competition here
TXMD vs ALVOW Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ALVOW has a market cap of 51.6M. Regarding current trading prices, TXMD is priced at $2.04, while ALVOW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ALVOW's P/E ratio is N/A. In terms of profitability, TXMD's ROE is +0.01%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, TXMD is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check ALVOW's competition here
TXMD vs JUPW Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TXMD is priced at $2.04, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TXMD's ROE is +0.01%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, TXMD is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check JUPW's competition here
TXMD vs QLI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TXMD is priced at $2.04, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas QLI's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is +0.01%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TXMD is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check QLI's competition here
TXMD vs ZYBT Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ZYBT has a market cap of 38.2M. Regarding current trading prices, TXMD is priced at $2.04, while ZYBT trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ZYBT's P/E ratio is -3.66. In terms of profitability, TXMD's ROE is +0.01%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, TXMD is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ZYBT's competition here
TXMD vs IXHL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, IXHL has a market cap of 35M. Regarding current trading prices, TXMD is priced at $2.04, while IXHL trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas IXHL's P/E ratio is -0.18. In terms of profitability, TXMD's ROE is +0.01%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, TXMD is more volatile compared to IXHL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check IXHL's competition here
TXMD vs SCYX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SCYX has a market cap of 32.2M. Regarding current trading prices, TXMD is priced at $2.04, while SCYX trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SCYX's P/E ratio is -1.33. In terms of profitability, TXMD's ROE is +0.01%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, TXMD is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SCYX's competition here
TXMD vs HEXO Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TXMD is priced at $2.04, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TXMD's ROE is +0.01%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TXMD is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check HEXO's competition here
TXMD vs RMTI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, RMTI has a market cap of 28M. Regarding current trading prices, TXMD is priced at $2.04, while RMTI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas RMTI's P/E ratio is -4.73. In terms of profitability, TXMD's ROE is +0.01%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, TXMD is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check RMTI's competition here
TXMD vs CYTH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TXMD is priced at $2.04, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TXMD's ROE is +0.01%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TXMD is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CYTH's competition here
TXMD vs QNTM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, QNTM has a market cap of 22.9M. Regarding current trading prices, TXMD is priced at $2.04, while QNTM trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas QNTM's P/E ratio is -0.66. In terms of profitability, TXMD's ROE is +0.01%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, TXMD is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check QNTM's competition here
TXMD vs OPTH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, TXMD is priced at $2.04, while OPTH trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas OPTH's P/E ratio is -5.50. In terms of profitability, TXMD's ROE is +0.01%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, TXMD is more volatile compared to OPTH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check OPTH's competition here
TXMD vs EVOK Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TXMD is priced at $2.04, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TXMD's ROE is +0.01%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, TXMD is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check EVOK's competition here
TXMD vs AYTU Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AYTU has a market cap of 17M. Regarding current trading prices, TXMD is priced at $2.04, while AYTU trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AYTU's P/E ratio is -0.46. In terms of profitability, TXMD's ROE is +0.01%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TXMD is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AYTU's competition here
TXMD vs TLPH Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, TLPH has a market cap of 15.9M. Regarding current trading prices, TXMD is priced at $2.04, while TLPH trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas TLPH's P/E ratio is -2.77. In terms of profitability, TXMD's ROE is +0.01%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, TXMD is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check TLPH's competition here
TXMD vs ACRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TXMD is priced at $2.04, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TXMD's ROE is +0.01%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, TXMD is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ACRX's competition here
TXMD vs COSM Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, COSM has a market cap of 14.2M. Regarding current trading prices, TXMD is priced at $2.04, while COSM trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas COSM's P/E ratio is -0.40. In terms of profitability, TXMD's ROE is +0.01%, compared to COSM's ROE of -0.96%. Regarding short-term risk, TXMD is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check COSM's competition here
TXMD vs BFRI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, BFRI has a market cap of 13.2M. Regarding current trading prices, TXMD is priced at $2.04, while BFRI trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas BFRI's P/E ratio is -1.05. In terms of profitability, TXMD's ROE is +0.01%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, TXMD is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check BFRI's competition here
TXMD vs AGRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TXMD is priced at $2.04, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TXMD's ROE is +0.01%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TXMD is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check AGRX's competition here
TXMD vs NLTX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TXMD is priced at $2.04, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TXMD's ROE is +0.01%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, TXMD is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check NLTX's competition here
TXMD vs YCBD Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, YCBD has a market cap of 7.9M. Regarding current trading prices, TXMD is priced at $2.04, while YCBD trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas YCBD's P/E ratio is 0.31. In terms of profitability, TXMD's ROE is +0.01%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TXMD is more volatile compared to YCBD. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check YCBD's competition here
TXMD vs LCI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TXMD is priced at $2.04, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas LCI's P/E ratio is -0.04. In terms of profitability, TXMD's ROE is +0.01%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TXMD is more volatile compared to LCI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check LCI's competition here
TXMD vs BGXX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $2.04, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas BGXX's P/E ratio is -0.76. In terms of profitability, TXMD's ROE is +0.01%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, TXMD is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check BGXX's competition here
TXMD vs ADMP Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $2.04, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TXMD's ROE is +0.01%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TXMD is more volatile compared to ADMP. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ADMP's competition here
TXMD vs EGRX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, EGRX has a market cap of 6.1M. Regarding current trading prices, TXMD is priced at $2.04, while EGRX trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas EGRX's P/E ratio is 6.57. In terms of profitability, TXMD's ROE is +0.01%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, TXMD is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check EGRX's competition here
TXMD vs MNK Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $2.04, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas MNK's P/E ratio is -0.44. In terms of profitability, TXMD's ROE is +0.01%, compared to MNK's ROE of -0.26%. Regarding short-term risk, TXMD is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check MNK's competition here
TXMD vs GELS Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $2.04, while GELS trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas GELS's P/E ratio is -0.95. In terms of profitability, TXMD's ROE is +0.01%, compared to GELS's ROE of -0.43%. Regarding short-term risk, TXMD is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check GELS's competition here
TXMD vs FLGC Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $2.04, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TXMD's ROE is +0.01%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, TXMD is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check FLGC's competition here
TXMD vs GHSI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $2.04, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas GHSI's P/E ratio is -0.79. In terms of profitability, TXMD's ROE is +0.01%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check GHSI's competition here
TXMD vs RDHL Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, RDHL has a market cap of 3.2M. Regarding current trading prices, TXMD is priced at $2.04, while RDHL trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas RDHL's P/E ratio is N/A. In terms of profitability, TXMD's ROE is +0.01%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, TXMD is more volatile compared to RDHL. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check RDHL's competition here
TXMD vs CPHI Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, CPHI has a market cap of 2.7M. Regarding current trading prices, TXMD is priced at $2.04, while CPHI trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas CPHI's P/E ratio is -1.59. In terms of profitability, TXMD's ROE is +0.01%, compared to CPHI's ROE of -0.00%. Regarding short-term risk, TXMD is more volatile compared to CPHI. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check CPHI's competition here
TXMD vs PLXP Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TXMD is priced at $2.04, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TXMD's ROE is +0.01%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TXMD is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for TXMD.Check PLXP's competition here
TXMD vs ATNX Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TXMD is priced at $2.04, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TXMD's ROE is +0.01%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TXMD is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check ATNX's competition here
TXMD vs SNOA Comparison June 2026
TXMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 23.6M. In comparison, SNOA has a market cap of 2M. Regarding current trading prices, TXMD is priced at $2.04, while SNOA trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 204.00, whereas SNOA's P/E ratio is -0.59. In terms of profitability, TXMD's ROE is +0.01%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, TXMD is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for TXMD.Check SNOA's competition here